Enlitic partners with Select Healthcare for early cancer detection
Category: #healthcare  By Mateen Dalal  Date: 2019-10-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Enlitic partners with Select Healthcare for early cancer detection

Artificial Intelligence in healthcare industry is set to be one of the highest revenues generating markets in the future due to the extraordinary benefits offered by this integrated system to the patients. Thus, collaborations between artificial intelligence firms and healthcare firms are increasingly being witnessed lately.

One such instance of a collaboration was observed recently when Enlitic, Inc., a pioneer in the field of medical deep learning and the software company behind the platform that integrates human as well as artificial intelligence (AI) to save lives, reportedly announced a strategic partnership with Select Healthcare Solutions, a San Diego based developer, operator and owner of state-of-the-art cancer centers throughout the U.S.

As a part of this agreement, Enlitic would receive access to the Select Healthcare’s anonymized, high-quality patient data, information that would further help Enlitic’s predictive models by fine-tuning them for early detection of cancer.

In exchange, Select HealthCare Solutions would receive access to software company’s top-of-the-class software technology. Additionally, Select would also directly contribute towards the future development of Enlitic products in oncology, radiology, and pathology.

Enlitic’s proprietary deep learning models have showcased amazing potential towards the detection of malignancies in their early stages. Reports cite, Enlitic's algorithm was learnt to recognize lung nodules having 91.1 percent sensitivity at the time of biopsy, working on par with state-of-the-art CAD, but also with much greater specificity.

Additionally, the algorithm was demonstrated to detect malignancies 12 and 6 months before the biopsy, and it reliably discovered cancerous nodules 17.5 months prior to when a biopsy was ordered.

Enlitic’s Chief Executive Officer, Kevin Lyman stated that oncology offers some of the healthcare industry’s most meaningful requirements for clinical AI, but alongside solutions that could only be built by using the right data as well as the right expertise.

Lyman added that Select HealthCare’s data would drastically boost the company’s research into the early recognition of several forms of cancer. Also, Select’s clinical expertise would help the company drive its best-in-class workflow solutions’ development for various oncology centers across the globe.

Chief Executive Officer and President of Select HealthCare Solutions, Matthew Cutler stated that Enlitic’s diagnostic artificial intelligence software is vital for enhancing patient care in the future and the company is thrilled to join Enlitic’s list of world-class partners by offering comprehensive multi-modal data which would help transform the way cancer is detected as well as treated.

Financial details pertaining to the strategic partnership have not been unveiled.

 

Source credit: https://www.businesswire.com/news/home/20191015006184/en/Enlitic-Announces-Strategic-Partnership-Select-Healthcare-Solutions

About Author

Mateen Dalal    

Mateen Dalal

Despite working as a professional testing engineer, Mateen Dalal always held a liking for content creation. Following his passion, he now pens down articles for itresearchbrief.com and a couple of similar portals. Mateen is a qualified electronics and telecommunicat...

Read More>>

More News By Mateen Dalal

Comcast confirms acquisition of free television streaming service Xumo
Comcast confirms acquisition of free television streaming service Xumo
By Mateen Dalal

The free-streaming video service comes installed on smart televisions and is ad-supported   ...

Clover partners with GSK for assessing coronavirus vaccine candidate
Clover partners with GSK for assessing coronavirus vaccine candidate
By Mateen Dalal

Burgeoning numbers of coronavirus cases have encouraged researchers to develop a viable vaccine cand...

Kadmon unveils expanded results from key trial of KD025 in cGVHD
Kadmon unveils expanded results from key trial of KD025 in cGVHD
By Mateen Dalal

Kadmon, a clinical-stage biopharmaceutical company, has reportedly announced expanded results from t...